
Sign up to save your podcasts
Or
Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
3.7
5353 ratings
Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
131 Listeners
325 Listeners
161 Listeners
865 Listeners
496 Listeners
281 Listeners
3,336 Listeners
90 Listeners
138 Listeners
1,095 Listeners
39 Listeners
185 Listeners
349 Listeners
427 Listeners
37 Listeners